Literature DB >> 24518495

The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.

Chang Moo Kang1, Michele L Babicky, Andrew M Lowy.   

Abstract

Pancreatic cancer remains a devastating disease with a mortality rate that has not changed substantially in decades. Novel therapies are therefore desperately needed. The RON receptor tyrosine kinase has been identified as an important mediator of KRAS oncogene addiction and is overexpressed in the majority of pancreatic cancers. Preclinical studies show that inhibition of RON function decreases pancreatic cancer cell migration, invasion, and survival and can sensitize pancreatic cancer cells to chemotherapy. This article reviews the current state of knowledge regarding RON biology and pancreatic cancer and discusses its potential as a therapeutic target.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24518495      PMCID： PMC4009395          DOI： 10.1097/MPA.0000000000000088

Source DB:  PubMed          Journal:  Pancreas        ISSN： 0885-3177            Impact factor:   3.327


  83 in total

1.  RON is associated with tumor progression via the inhibition of apoptosis and cell cycle arrest in human gastric cancer.

Authors:  Young-A Song; Young-Lan Park; Kyu-Yeol Kim; Eun Myung; Cho-Yun Chung; Sung-Bum Cho; Wan-Sik Lee; Young-Do Jung; Sun-Seog Kweon; Young-Eun Joo
Journal:  Pathol Int       Date:  2011-11-28       Impact factor: 2.534

2.  Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of HSP90 inhibitors.

Authors:  Christian Moser; Sven A Lang; Christina Hackl; Hong Zhang; Karen Lundgren; Victor Hong; Andres McKenzie; Bernhard Weber; Jung S Park; Hans J Schlitt; Edward K Geissler; Young D Jung; Oliver Stoeltzing
Journal:  Anticancer Res       Date:  2012-02       Impact factor: 2.480

3.  Plectin-1 as a novel biomarker for pancreatic cancer.

Authors:  Dirk Bausch; Stephanie Thomas; Mari Mino-Kenudson; Castillo Carlos Fernández-del; Todd W Bauer; Mark Williams; Andrew L Warshaw; Sarah P Thayer; Kimberly A Kelly
Journal:  Clin Cancer Res       Date:  2010-11-23       Impact factor: 12.531

4.  Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.

Authors:  Snehal S Padhye; Sunny Guin; Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Mol Pharm       Date:  2011-11-01       Impact factor: 4.939

5.  Expression of the recepteur d'originenantais receptor tyrosine kinase in non-small cell lung cancer and its clinical significance.

Authors:  Wei-li Han; Wei-dong Li; Jian Hu; Aizemaiti Rusidanmu; Ling-fang Chen; Ling Shen; Shu-sen Zheng
Journal:  Chin Med J (Engl)       Date:  2012-03       Impact factor: 2.628

6.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

7.  Ron kinase transphosphorylation sustains MET oncogene addiction.

Authors:  Silvia Benvenuti; Luca Lazzari; Addolorata Arnesano; Giulia Li Chiavi; Alessandra Gentile; Paolo M Comoglio
Journal:  Cancer Res       Date:  2011-01-06       Impact factor: 12.701

8.  A combination of DR5 agonistic monoclonal antibody with gemcitabine targets pancreatic cancer stem cells and results in long-term disease control in human pancreatic cancer model.

Authors:  N V Rajeshkumar; Zeshaan A Rasheed; Elena García-García; Fernando López-Ríos; Kosaku Fujiwara; William H Matsui; Manuel Hidalgo
Journal:  Mol Cancer Ther       Date:  2010-07-26       Impact factor: 6.261

Review 9.  Hsp90 molecular chaperone inhibitors: are we there yet?

Authors:  Len Neckers; Paul Workman
Journal:  Clin Cancer Res       Date:  2012-01-01       Impact factor: 12.531

10.  RON is not a prognostic marker for resectable pancreatic cancer.

Authors:  Carole M Tactacan; David K Chang; Mark J Cowley; Emily S Humphrey; Jianmin Wu; Anthony J Gill; Angela Chou; Katia Nones; Sean M Grimmond; Robert L Sutherland; Andrew V Biankin; Roger J Daly
Journal:  BMC Cancer       Date:  2012-09-07       Impact factor: 4.430
View more
  11 in total

1.  A missing link between RON expression and oncological outcomes in resected left-sided pancreatic cancer.

Authors:  Dai Hoon Han; Chang Moo Kang; Sung Whan Lee; Ho Kyoung Hwang; Woo Jung Lee
Journal:  Oncol Lett       Date:  2017-08-01       Impact factor: 2.967

2.  Norleual, a hepatocyte growth factor and macrophage stimulating protein dual antagonist, increases pancreatic cancer sensitivity to gemcitabine.

Authors:  Kevin J Church; Brett R Vanderwerff; Rachelle R Riggers; Beatriz Mateo-Victoriano; Matthew Fagnan; Phillip H Harris; Jewel C LeValley; Joseph W Harding
Journal:  Anticancer Drugs       Date:  2018-04       Impact factor: 2.248

3.  Analogs of the hepatocyte growth factor and macrophage-stimulating protein hinge regions act as Met and Ron dual inhibitors in pancreatic cancer cells.

Authors:  Kevin J Church; Brett R Vanderwerff; Rachelle R Riggers; Michelle D McMicheal; Beatriz Mateo-Victoriano; Sudharsan R Sukumar; Joseph W Harding
Journal:  Anticancer Drugs       Date:  2016-09       Impact factor: 2.248

4.  Pancreatic cancer patient survival correlates with DNA methylation of pancreas development genes.

Authors:  Michael J Thompson; Liudmilla Rubbi; David W Dawson; Timothy R Donahue; Matteo Pellegrini
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

Review 5.  Roles of c-Met and RON kinases in tumor progression and their potential as therapeutic targets.

Authors:  Katherine Chang; Anand Karnad; Shujie Zhao; James W Freeman
Journal:  Oncotarget       Date:  2015-02-28

6.  Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma.

Authors:  Chihiro Sakugawa; Yukihiro Haruyama; Hiroyuki Tanaka; Tsuyoshi Fukushima; Makiko Kawaguchi; Hiroaki Kataoka
Journal:  BMC Res Notes       Date:  2017-12-04

7.  Human Mesenchymal Stem Cell-Derived Exosomal microRNA-143 Promotes Apoptosis and Suppresses Cell Growth in Pancreatic Cancer via Target Gene Regulation.

Authors:  Bingyi Wang; Yan Xu; Yuhua Wei; Lixin Lv; Nanbin Liu; Rui Lin; Xiuyan Wang; Baomin Shi
Journal:  Front Genet       Date:  2021-02-12       Impact factor: 4.599

8.  A potential signaling axis between RON kinase receptor and hypoxia-inducible factor-1 alpha in pancreatic cancer.

Authors:  Akihisa Kato; Serina Ng; Amalraj Thangasamy; Haiyong Han; Wendi Zhou; Stephane Raeppel; Michael Fallon; Sushovan Guha; Sudhakar Ammanamanchi
Journal:  Mol Carcinog       Date:  2021-08-04       Impact factor: 5.139

Review 9.  Role of Recepteur D'origine Nantais on Gastric Cancer Development and Progression.

Authors:  Sung Yeul Yang; Thi Thinh Nguyen; Trong Thuan Ung; Young Do Jung
Journal:  Chonnam Med J       Date:  2017-09-25

10.  Identification of candidate genes related to pancreatic cancer based on analysis of gene co-expression and protein-protein interaction network.

Authors:  Tiejun Zhang; Xiaojuan Wang; Zhenyu Yue
Journal:  Oncotarget       Date:  2017-08-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.